

Smartphone addiction as a risk factor for medication non-adherence in renal transplant recipients

Özant Helvacı^{1*}, Asil Demirezen¹, Ömer Faruk Akçay¹, Muhammed Hakan Aksu², Ulver Derici¹

¹Department of Nephrology, Faculty of Medicine, Gazi University Ankara, Turkey

²Department of Psychiatry, Faculty of Medicine, Gazi University, Ankara, Turkey

Submitted: 1 February 2025; **Accepted:** 10 August 2025

Online publication: 26 October 2025

Arch Med Sci 2025; 21 (6): 2328–2337

DOI: <https://doi.org/10.5114/aoms/209207>

Copyright © 2025 Termedia & Banach

***Corresponding author:**

Özant Helvacı MD
Department of Nephrology
Faculty of Medicine
Gazi University
Ankara, Turkey
Phone: +90 312 202 52 29
E-mail: ozanthelvacı@gazi.edu.tr

Abstract

Introduction: Medication non-adherence (MNA) is a leading cause of graft loss and mortality in renal transplant recipients. Smartphone addiction (SPA) is associated with cognitive impairment and poor time management, but its relationship with MNA remains unclear. This is the first study to investigate the association between SPA and MNA in renal transplant recipients.

Material and methods: This cross-sectional study included 140 renal transplant recipients. SPA was assessed using the Smartphone Addiction Scale-Short Version (SAS-SV) and weekly screen time. MNA was measured using the Immunosuppressant Therapy Adherence Scale (ITAS), classifying adherence as perfect (12), acceptable (10–11), or poor (≤ 9). Univariate and multivariate logistic regression were performed to identify predictors of MNA.

Results: Patients with poor adherence had longer weekly screen time (27 ± 10 h) than those with perfect (20 ± 10 h) or acceptable adherence (21 ± 11 h) ($p < 0.001$). The poor adherence group had a higher prevalence of SPA (66%) than the perfect (38%) and acceptable adherence groups (36%) ($p = 0.020$). In univariate analysis, higher SAS-SV scores ($p = 0.006$) and weekly screen time ($p = 0.006$) were associated with MNA. In multivariate analysis, only weekly screen time > 22 h remained an independent predictor (OR = 4.106, 95% CI: 1.366–12.336, $p = 0.012$), while SAS-SV scores lost significance.

Conclusions: Excessive smartphone use, particularly prolonged screen time, is independently associated with MNA in renal transplant recipients. Integrating screen time tracking into routine transplant care may help identify at-risk patients. Future studies should determine whether reducing screen exposure improves adherence.

Key words: medication adherence, medication non-adherence, renal transplantation, smartphone addiction, transplant recipients, behavioral risk factors.

Introduction

Kidney transplantation is the preferred treatment for end-stage kidney disease [1]. Long-term graft survival remains a major challenge in renal transplantation despite advancements in short-term outcomes. A key modifiable factor that greatly influences graft survival is medication non-adherence (MNA) [2, 3]. MNA is widely recognized as a major contributor to graft loss, rejection, and mortality in renal transplant recipients [4]. Younger age, depression, low health literacy, and complex medication regimens contribute to MNA [2, 4, 5].

Smartphone addiction (SPA) is characterized by compulsive smartphone use despite negative consequences, impairing self-regulation and cognitive function [6]. SPA is linked to mental health issues such as anxiety and depression, as well as physical effects such as sleep disruption and increased sedentary behavior [6–9]. Severe SPA disrupts executive functions, including time management, attention, and impulse control, which are essential for medication adherence [10–12].

Psychological and socioeconomic factors are well-recognized contributors to MNA, yet the influence of modern digital behaviors, such as excessive smartphone use, remains largely unexplored. Existing research primarily highlights the short-term benefits of smartphone applications in promoting medication adherence through structured interventions. However, these interventions often lose effectiveness over time, and their long-term impact remains unclear [2, 13].

Evidence suggests that SPA and MNA share overlapping behavioral mechanisms. Based on these insights, we propose that SPA may be a risk factor for MNA in renal transplant recipients. This cross-sectional study provides the first investigation of the association between SPA and MNA in renal transplant recipients.

Material and methods

Participants

This cross-sectional study was conducted at the Gazi University Faculty of Medicine Transplant Outpatient Unit between July and October 2024 and included only renal transplant recipients. Participants were consecutively recruited during routine clinic visits, and all eligible individuals were invited to participate.

The inclusion criteria required participants to be over 18 years of age, under follow-up as renal transplant recipients for at least 12 months, own a smartphone, have adequate cognitive capacity to complete the questionnaires and provide informed consent.

Exclusion criteria included individuals under 18 years, those declining informed consent, non-smartphone users or those unable to operate a smartphone independently, patients with cognitive impairments or mental health conditions preventing questionnaire completion, current use of medication reminder apps, and individuals prescribed psychotropic medications, including but not limited to antidepressants, antipsychotics, benzodiazepines, or mood stabilizers, which may affect cognitive function. The recruitment process is presented in a flowchart (Figure 1).

Data collection

Demographic and clinical data, including age, gender, marital status, literacy level, economic status, donor type (living or deceased), transplant type (preemptive or non-preemptive), dialysis vintage for non-preemptive transplants, history of rejection, comorbidities, current creatinine, estimated glomerular filtration rate (eGFR, CKD-EPI 2021), immunosuppressive therapy (IS) burden, and total pill burden, were extracted from patient charts. Complete data were available for all variables.

Smartphone addiction was assessed using the Smartphone Addiction Scale-Short Version (SAS-SV), developed by Kwon *et al.* in 2013 as a shorter version of the original scale [14]. The SAS-SV consists of 10 items, each scored up to 6 points, with higher scores indicating a greater risk of smartphone addiction. The scale has been validated for the Turkish population [15]. This study used the cohort's mean score as the cut-off for addiction risk. Participants' weekly screen times (hours) were retrieved from their smartphones as another measure of addiction or misuse. Weekly screen time was dichotomized using the cohort mean to create high and low exposure groups for statistical analysis.

Adherence to immunosuppressive therapy was evaluated using the Immunosuppressant Therapy Adherence Scale (ITAS), adapted for transplant recipients by Chisholm *et al.* in 2005 [16]. The ITAS consisted of four questions assessing adherence behavior over the past 3 months, with response categories of 0%, 1–20%, 21–50%, and over 50%. Scores range from 0 to 12, where higher scores indicate better adherence. The scale was validated for Turkish populations by Madran *et al.* [17]. Although the original ITAS scoring classifies only a score of 12 as full adherence, alternative catego-




Figure 1. Flowchart of patient recruitment

rizations classify 12 as perfect adherence, 10–11 as acceptable adherence, and 0–9 as non-adherence [18]. This alternative scoring was adopted in this study, as minor deviations in adherence are frequent among transplant recipients and may not impact clinical outcomes [19]. Furthermore, the original scoring approach potentially overestimates non-adherence, whereas this adjusted categorization accurately reflects adherence patterns, as highlighted by Promraj *et al.* [20].

Terminology

Terminology for smartphone-related behaviors remains inconsistent, with terms such as excessive use, problematic use, and addiction often used interchangeably [21, 22]. This paper uses smartphone addiction (SPA) as an umbrella term for these related concepts.

Statistical analysis

Data were analyzed using SPSS v22.0. Descriptive statistics included means and standard deviations for continuous variables and frequencies and percentages for categorical variables. The Shapiro-Wilk test assessed normality. For group comparisons, independent *t*-tests or Mann-Whitney *U* tests were applied to continuous variables, while χ^2 tests were used for categorical variables, with Bonferroni's correction for post-hoc evaluations if needed. Pearson's correlation was used for normally distributed variables and Spearman's correlation for non-normal data. Correlation strength was classified as weak (< 0.3), moderate

(0.3–0.7), or strong (> 0.7) [23]. A *p*-value < 0.05 was considered significant.

Univariate analyses evaluated associations between potential predictors and MNA. Variables with $p < 0.1$ in univariate analysis were entered into the multivariate logistic regression model to identify independent predictors of MNA and SPA. Adjusted odds ratios (ORs) and 95% confidence intervals (CIs) were reported for significant associations.

The sample size was calculated using Cochran's formula, based on an estimated 10% prevalence of smartphone addiction among renal transplant recipients and a 5% margin of error. With a 95% confidence level, the required sample size was 138 participants, ensuring sufficient power to detect associations.

This cross-sectional study was reported in accordance with STROBE guidelines.

Results

Patient characteristics

The study included 140 renal transplant recipients, with a mean age of 44 ± 12 years. The majority were male (60%) and married (72.9%). Educational levels varied, with 48.6% having a university degree or higher, 39.3% completing middle or high school, 11.4% attending elementary school, and 0.7% being illiterate. The income distribution was 25.7% low, 47.9% middle, and 26.4% high.

Hypertension was the most common comorbidity, affecting 67% of participants. Diabetes mellitus was present in 17%, while 7% had post-transplant diabetes. Coronary artery disease affected 10% of patients, and 22.9% were active smokers (Table I).

Table I. Patient characteristics

Characteristic	Results
Age [years]	44 \pm 12
Sex (female/male)	56/84 (40/60%)
Marital status (married/not married)	102/38 (72.9/27.1%)
Educational status	
Illiterate	1 (0.7%)
Elementary school	16 (11.4%)
Middle or high school	55 (39.3%)
University or higher	68 (48.6%)
Income	
Low	36 (25.7%)
Middle	67 (47.9%)
High	37 (26.4%)
Hypertension (present)	94 (67%)
Diabetes mellitus (present)	24 (17%)
Post-transplant diabetes (present)	11 (7%)
Coronary artery disease (present)	15 (10%)
Active smoker (yes)	32 (22.9%)

Transplant characteristics and medication burden

Most transplants were from living donors (79.3%), with 26.4% being preemptive. The mean duration of renal replacement therapy prior to transplantation was 4.9 ± 4.6 years, while the average post-transplant follow-up period was 9.7 ± 6.1 years.

Eleven (7.9%) patients had undergone a second transplant, and 17.1% had experienced rejection episodes. The mean daily immunosuppressive pill burden was 7 ± 2 pills, with a total daily pill burden of 11 ± 4 . The mean serum creatinine level was 1.36 ± 0.74 mg/dl, and the mean eGFR was 69.0 ± 24.2 ml/min (Table II).

Smartphone usage patterns and adherence levels

The mean SAS-SV score was 23 ± 10 , with 42% scoring above this threshold, indicating a higher risk of smartphone addiction. Weekly screen time aver-

aged 21.9 ± 10.7 h, with 40% exceeding 22 h per week. Social media was the primary use of smartphones for 59% of participants, followed by entertainment and education, at 17% each (Table III).

Regarding medication adherence, the mean ITAS score was 10.5 ± 1.7 ; 33% of participants showed perfect adherence, 47% showed acceptable adherence, and 19% were classified as non-adherent (Table III).

Demographic and transplant-related factors across adherence groups

As shown in Table IV, demographic factors, including age, sex, marital status, educational level, and income, did not differ significantly across adherence groups (all $p > 0.05$). While the proportion of unmarried participants was higher in the poor adherence group compared to the other groups, this difference was not statistically significant.

Transplant-related characteristics, such as donor type, history of rejection, preemptive transplantation, and duration of renal replacement therapy or transplant follow-up, were similarly distributed across all adherence groups. Clinical parameters, including immunosuppressive pill burden, total pill burden, serum creatinine levels, and eGFR, also showed no significant differences between the groups (all $p > 0.05$).

Smartphone addiction and screen time by adherence level

SAS-SV and weekly screen time both demonstrated significant differences across adherence groups. The poor adherence group had a higher mean SAS-SV score (28 ± 10) compared to the perfect (22 ± 9) and acceptable adherence groups (22 ± 11), with post-hoc analysis revealing significant differences between the poor and perfect adherence groups ($p = 0.039$) as well as between the poor and acceptable adherence groups ($p = 0.018$).

Table II. Transplant-related patient characteristics

Characteristic	Results
Donor type (living/deceased)	111/ 29 (79.3/20.7%)
Preemptive transplantation (yes)	37 (26.4%)
Years of RRT before transplant*	4.9 ± 4.6 (1–20)
Transplant duration	9.7 ± 6.1 (1–32)
Second transplant (yes)	11 (7.9%)
History of rejection episode	24/116
Immunosuppressive pill burden**	7 ± 2 (3–14)
Total pill burden**	11 ± 4 (5–28)
Creatinine [mg/dl]	1.36 ± 0.74
eGFR (CKD-EPI 2021) [ml/min]	69.0 ± 24.2

*If not preemptive, **rounded to closest integer.

A significantly higher proportion of patients in the poor adherence group exceeded the SAS-SV threshold score of 23 (66% vs. 38% in the perfect and 36% in the acceptable adherence groups, $p = 0.020$).

Weekly screen time was also significantly elevated in the poor adherence group (27 ± 10 h) compared to the perfect (20 ± 10 h, $p = 0.021$) and acceptable adherence groups (21 ± 11 h, $p = 0.024$). Additionally, 74% of patients in the poor adherence group reported screen time exceeding 22 h per week, in contrast to 34% in the perfect adherence group and 31% in the acceptable adherence group ($p < 0.001$) (Table V). Spearman's correlation analysis revealed a weak but significant inverse association between medication non-adherence levels and SAS-SV scores, weekly screen time, and related variables (Table VI).

Factors influencing medication non-adherence

Univariate analysis identified several significant predictors of MNA. Higher SAS-SV scores were inversely associated with adherence (OR = 0.947, 95% CI: 0.911–0.985, $p = 0.006$), as was weekly screen time (OR = 0.949, 95% CI: 0.915–0.986, $p = 0.006$). Participants with SAS-SV scores above 23 were significantly more likely to exhibit MNA (OR = 3.381, 95% CI: 1.393–8.204, $p = 0.007$), while those with weekly screen time exceeding 22 h showed the strongest association (OR = 5.869, 95% CI: 2.278–15.117, $p < 0.001$).

Table III. Smartphone addiction and drug adherence scores

Characteristic	Results
SAS-SV score	23 ± 10 (10–56)
SAS-SV score	
> 23	60 (42%)
≤ 23	80 (58%)
Weekly screen time on phone [h]	21.9 ± 10.7
Weekly screen time on phone [h]	
> 22	57 (40%)
≤ 22	83 (60%)
Most common use of smartphone*	
Entertainment	25 (17%)
Gaming	7 (5%)
Social media	83 (59%)
Education	25 (17%)
ITAS score	10.5 ± 1.7
ITAS score*	
12 (perfect adherence)	47 (33%)
10, 11 (acceptable adherence)	66 (47%)
≤ 9 (non-adherence)	27 (19%)

*May not add up to 100 because of rounding.

Table IV. Demographic, transplant, and clinical characteristics by adherence group

Parameter	Perfect adherence Group A (n = 47)	Acceptable adherence Group B (n = 66)	Poor adherence Group C (n = 27)	P-value
Age	43 ±12	46 ±12	38 ±10	0.091
Sex (female/male)	15/32	28/38	13/14	0.335
Marital status (unmarried, %)	12 (25.5%)	14 (21.2%)	12 (44.4%)	0.070
Educational status				0.377
Illiterate	0	0	1	
Elementary school	6	8	2	
Middle or high school	15	29	11	
University or higher	26	29	13	
Income				0.526
Low	16	13	7	
Middle	20	35	12	
High	11	18	18	
Diabetes	6	3	2	0.276
Hypertension	16	43	35	0.364
Active smoker	14	15	3	0.183
Transplantation-related parameters				
Donor type (living/deceased)	37/10	51/15	23/4	0.689
Second transplant	4	6	1	0.622
Preemptive transplant	13	17	7	0.973
History of rejection	9	9	6	0.551
Transplant duration	10 ±7	10 ±6	10 ±7	0.805
RRT duration	5 ±4	5 ±4	5 ±5	0.923
IS pill count	7 ±2	6 ±2	7 ±2	0.770
Total pill count	11 ±4	11 ±4	12 ±4	0.612
Creatinine	1.36 ±0.53	1.34 ±0.64	1.46 ±0.67	0.767
eGFR	68 ±23	67 ±23	73 ±27	0.611

Table V. Smartphone addiction and usage patterns by adherence group

Parameter	Perfect adherence Group A (n = 47)	Acceptable adherence Group B (n = 66)	Poor adherence Group C (n = 27)	P-value	Post-hoc comparison
SAS-SV score	22 ±9	22 ±11	28 ±10	0.015	A vs. C = 0.039 B vs. C = 0.018 A vs. B = 0.999
SAS-SV score > 23	18 (38%)	24 (36%)	18 (66%)	0.020	A vs. C = 0.019 B vs. C = 0.008 A vs. B = 0.834
Weekly screen time on the phone	20 ±10	21 ±11	27 ±10	0.014	A vs. C = 0.021 B vs. C = 0.024 A vs. B = 0.879
Weekly screen time > 22 h	16 (34%)	21 (31%)	20 (74%)	0.000	A vs. C = 0.001 B vs. C = 0.000 A vs. B = 0.804

In multivariate analysis, only weekly screen time exceeding 22 h remained a significant independent predictor of MNA (Model 2: OR = 4.106, 95% CI: 1.366–12.336, $p = 0.012$). Other variables, including age and marital status, lost significance after adjustment (Table VII).

Discussion

This study is the first to demonstrate that SPA is associated with MNA in renal transplant recipients, with objectively measured screen time emerging as a stronger predictor than self-reported addiction scores. Although SPA cannot be the sole determinant of MNA, our findings highlight its role as a behavioral factor that warrants further study.

Patients with poor adherence exhibited significantly higher weekly screen time and SAS-SV scores. In univariate analysis, both SAS-SV scores and weekly screen time were associated with MNA; however, in multivariate models, only weekly screen time > 22 h remained a significant independent predictor (OR = 4.106, $p = 0.012$), whereas SAS-SV scores lost statistical significance ($p = 0.206$). This finding highlights that screen time, rather than perceived addiction, may be a more reliable predictor of adherence. A similar distinction was demonstrated by Anderl *et al.*, who showed that logged screen use more accurately predicted psychosocial outcomes than self-reported estimates [23].

Correlation analysis reinforces these findings, demonstrating weak but statistically significant

Table VI. Correlation with adherence levels (Spearman's rho)

Variable	<i>r</i> -value	<i>P</i> -value
SAS-SV score	−0.181	0.032
SAS-SV score > 23	−0.174	0.040
Weekly screen time	−0.197	0.020
Weekly screen time > 22	−0.233	0.006

negative associations between adherence levels, SAS-SV scores ($r = -0.181$, $p = 0.032$), and weekly screen time ($r = -0.197$, $p = 0.020$). These findings reinforce that MNA is multifactorial rather than driven by a single behavioral determinant [2].

Younger age is frequently cited as a risk factor for non-adherence, particularly among adolescents and young adults [10, 24–26]. Among adolescents and young adults, non-adherence has been reported to account for 44% of graft losses and 23% of late acute rejection episodes [2, 25]. Our study, which included only adults, did not support this association, likely due to the absence of younger participants. It is possible that the association between younger age and non-adherence would be more pronounced in a cohort including adolescents.

The role of demographic and transplant-related factors, including donor type, rejection history, preemptive transplantation, and pill burden, in MNA remains debated, with conflicting evidence in the literature [27–30]. In our study, these variables did not significantly differ between adherence groups, suggesting that traditional clinical

Table VII. Univariate and multivariate analysis of factors influencing MNA

Variable	Univariate, OR (95% CI)	<i>P</i> -value	Multivariate, OR (95% CI) Model 1	<i>P</i> -value	Multivariate, OR (95% CI) Model 2	<i>P</i> -value
Age	1.036 (0.999–1.075)	0.060	1.009 (0.963–1.058)	0.701	1.001 (0.955–1.049)	0.982
Gender (male)	0.662 (0.284–1.540)	0.338				
Marital status	2.677 (1.114–6.431)	0.028	0.546 (0.180–1.655)	0.286	0.625 (0.204–1.918)	0.411
Education	1.200 (0.001–8.196)	0.935				
Income	0.931 (0.520–1.667)	0.811				
RRT [years]	0.990 (0.893–1.098)	0.848				
Donor type (living)	0.612 (0.194–1.935)	0.403				
Transplant vintage	0.978 (0.915–1.045)	0.510				
IS pill count	0.921 (0.737–1.151)	0.469				
Total pill count	1.003 (0.907–1.109)	0.952				
eGFR	0.991 (0.974–1.009)	0.325				
History of rejection	1.508 (0.534–4.257)	0.438				
SAS-SV score	0.947 (0.911–0.985)	0.006	0.967 (0.917–1.032)	0.206		
Weekly screen time	0.949 (0.915–0.986)	0.006	0.979 (0.929–1.032)	0.429		
SAS-SV score > 23	3.381 (1.393–8.204)	0.007			1.647 (0.597–4.547)	0.335
Weekly screen time > 22	5.869 (2.278–15.117)	0.000			4.106 (1.366–12.336)	0.012

cal risk factors alone may not fully explain MNA in our cohort.

The prevalence of MNA in the literature ranges from 10% to 60%, influenced by specific questionnaires, criteria, and populations examined [2, 5, 28, 31, 32]. The consistent results observed in two studies conducted in our country support the validity of our findings, with 23% of patients being classified as non-adherent [27, 29].

SPA has been associated with cognitive impairments in attention, impulse control, time management, and structural brain changes in some studies [11, 12, 33–35]. These cognitive disruptions could lead to missed medication doses, particularly in patients with complex regimens. Additionally, excessive smartphone use disrupts sleep patterns, possibly impacting adherence [9, 36, 37].

A key strength of this study is the use of objectively recorded screen time rather than relying solely on self-reported SPA measures. According to Judice *et al.*, self-reported screen time underestimates actual usage by over 70 min daily, reinforcing the need for objective metrics [38]. Prior research indicates a strong association between increased screen time and negative behavioral health outcomes, supporting screen time as a relevant behavioral marker in adherence research [39, 40]. However, although screen time offers an objective measure, it does not differentiate between productive (e.g., educational or medically relevant) and unproductive (e.g., social media or gaming) use [41]. Future studies should incorporate app-specific tracking to better capture these distinctions.

Some studies suggest that e-health applications can improve medication adherence; however, their long-term effects on clinical outcomes remain uncertain [42]. Hartch *et al.* demonstrated that a medication adherence app significantly enhanced adherence and self-efficacy among medically underserved adults with chronic illnesses, although they stated that their approach's impact on long-term clinical outcomes was not established [13]. Only 4 out of 198 ($\approx 2\%$) of our initial cohort reported using applications to enhance medication adherence (Figure 1). We believe omitting these patients did not have any impact on our results. However, further trials may show the help of apps in renal transplant recipients.

The low percentage of medication app users ($\approx 2\%$) in our cohort is primarily a function of age and educational demographics, as digital health tool adoption typically requires structured interventions rather than spontaneous uptake. Research demonstrates that only 2.6% of adults aged 62+ use medication reminder apps, with older patients showing significantly lower adoption rates [43]. Furthermore, patients with chronic diseases

paradoxically show lower app adoption rates (6.6%) compared to healthy individuals (38.9%), despite greater need for medication management tools [44]. This suggests that structured digital health interventions with demographic-specific support may be necessary to overcome adoption barriers in transplant populations.

Mitigation strategies for SPA, including behavioral interventions, structured usage plans, and controlled smartphone use, could help reduce its negative impact. Studies show both successful and unsuccessful interventions [45]. Olson *et al.* implemented a nudge-based approach – such as disabling notifications, setting the screen to grayscale, and keeping phones out of reach – that reduced problematic smartphone use and screen time in the short term; however, long-term adherence and effects on depression diminished over time [46].

Smartphone-based adherence interventions have shown promising but variable results: the SMASK (Smartphone Medication Adherence Saves Kidneys) trial's pilot phase showed improved immunosuppressive adherence from 56% to 92% and reduced mean systolic blood pressure by 12 mm Hg. However, no subsequent reports have confirmed the durability of these gains [47]. A recent meta-analysis of 12 randomized trials involving 1 234 renal transplant recipients rated overall evidence as low quality due to high methodological heterogeneity, small sample sizes, and short follow-up and determined that the current evidence remains inconclusive [48]. Key barriers include fragmented IT systems, inconsistent digital literacy, and scarce long-term data. Implementing phased, small-scale pilots with dedicated teams and standardized metrics can address logistical challenges. Future multicenter randomized controlled trials with longer follow-up on hard outcomes are needed to validate durability and clinical impact [49].

One of the primary strengths of this study is its pioneering nature, as it is among the first to explore the relationship between SPA and MNA in renal transplant recipients, providing a valuable foundation for future research. Additionally, using validated scales for assessing both SPA and MNA enhances the reliability of the findings. A notable strength is the inclusion of weekly screen time as an objective, device-recorded metric, reducing reliance on potentially biased self-reported data.

This study has certain limitations that must be considered when interpreting the results. The cross-sectional design does not allow for causal inference and temporal directionality, making it unclear whether excessive smartphone use drives MNA or pre-existing behavioral tendencies contribute to both. Future longitudinal studies are needed to clarify the causality of this relationship.

onship. Additionally, psychiatric comorbidities were not systematically assessed. While we excluded patients using psychotropic medications, undiagnosed conditions such as depression and anxiety could still have influenced smartphone use and adherence behaviors. Further research incorporating validated psychiatric assessments is warranted.

Furthermore, while screen time serves as an objective measure of smartphone engagement, it does not differentiate between productive (e.g., educational) and non-productive (e.g., excessive social media) use. Future studies should explore which specific smartphone behaviors contribute most to MNA. The weekly screen time threshold of 22 h was established using our population's mean, as no validated clinical thresholds exist for smartphone screen time in this context. This population-specific approach may limit generalizability, as optimal cut-offs may vary across different patient demographics and geographic regions. Although we checked for formal psychiatric diagnoses and previous medication history, we did not have the resources to conduct face-to-face psychiatric evaluations for each patient, which is a limitation of our study. Future research should incorporate systematic psychiatric assessments to better understand these potential confounding factors.

As this was a single-center study with an acceptable number of subjects, the findings may not be generalizable to all transplant populations, emphasizing the need for larger, multicenter, and longitudinal investigations.

In conclusion, this study highlights excessive smartphone use, particularly prolonged screen time, as a novel behavioral risk factor for MNA in renal transplant recipients. Incorporating screen time monitoring into routine transplant follow-up may provide a scalable method for identifying at-risk patients. Our findings suggest that routine screen time tracking could be a practical, low-burden screening tool in transplant follow-up. Given the increasing reliance on smartphones, future research should explore interventions that balance the benefits of mobile health tools with the risks of excessive digital engagement. Integrating SPA management into post-transplant care may represent an important yet overlooked strategy for improving long-term graft survival.

Acknowledgments

During the preparation of this work, the authors used ChatGPT-4o to achieve clarity, coherence, and grammatical accuracy. After using these tools, the authors reviewed and edited the content as needed and take full responsibility for the publication's content.

Funding

No external funding.

Ethical approval

Ethical approval was obtained from the Gazi University Ethics Committee on July 9, 2024 (Approval number: E-77082166-604.01-996596). The study adhered to the Declaration of Helsinki principles, including respect for individuals, informed consent, and participant safeguards.

Conflict of interest

The authors declare no conflict of interest.

References

1. Tonelli M, Wiebe N, Knoll G, et al. Systematic review: kidney transplantation compared with dialysis in clinically relevant outcomes. *Am J Transplant* 2011; 11: 2093-109.
2. Gandolfini I, Palmisano A, Fiaccadori E, Cravedi P, Maggiore U. Detecting, preventing and treating non-adherence to immunosuppression after kidney transplantation. *Clin Kidney J* 2022; 15: 1253-74.
3. Denhaerynck K, Burkhalter F, Schafer-Keller P, Steiger J, Bock A, De Geest S. Clinical consequences of non adherence to immunosuppressive medication in kidney transplant patients. *Transpl Int* 2009; 22: 441-6.
4. TRabulus S. Old but still a significant problem: medication nonadherence in transplant recipients. *Turk J Nephrol* 2023; 32: 255-9.
5. Morrissey PE, Flynn ML, Lin S. Medication noncompliance and its implications in transplant recipients. *Drugs* 2007; 67: 1463-81.
6. Li J, Yang H. Unveiling the grip of mobile phone addiction: an in-depth review. *Front Psychiatry* 2024; 15: 1429941.
7. Al-Hadidi F, Bsisu I, AlRyalat SA, et al. Association between mobile phone use and neck pain in university students: a cross-sectional study using numeric rating scale for evaluation of neck pain. *PLoS One* 2019; 14: e0217231.
8. Demir YP, Sumer MM. Effects of smartphone overuse on headache, sleep and quality of life in migraine patients. *Neurosciences* 2019; 24: 115-21.
9. Wacks Y, Weinstein AM. Excessive smartphone use is associated with health problems in adolescents and young adults. *Front Psychiatry* 2021; 12: 669042.
10. Alhassan AA, Alqadhib EM, Taha NW, Alahmari RA, Salam M, Almutairi AF. The relationship between addiction to smartphone usage and depression among adults: a cross sectional study. *BMC Psychiatry* 2018; 18: 148.
11. Ratan ZA, Parrish AM, Zaman SB, Alotaibi MS, Hosseinzadeh H. Smartphone addiction and associated health outcomes in adult populations: a systematic review. *Int J Environ Res Public Health* 2021; 18: 12257.
12. Choksi ST. A study to find out the correlation of mobile phone addiction with anxiety, depression, stress and sleep quality in the college students of Surat City. *Int J Curr Res Rev* 2021; 13: 137-42.
13. Hartch CE, Dietrich MS, Lancaster BJ, Stollendorf DP, Mulvaney SA. Effects of a medication adherence app among

- medically underserved adults with chronic illness: a randomized controlled trial. *J Behav Med* 2024; 47: 389-404.
14. Kwon M, Kim DJ, Cho H, Yang S. The smartphone addiction scale: development and validation of a short version for adolescents. *PLoS One* 2013; 8: e83558.
 15. Demirci K, Orhan H, Demirdas A, Akpinar A, Sert H. Validity and reliability of the Turkish version of the smartphone addiction scale in a younger population. *Klinik Psikofarmakoloji Bülteni-Bulletin of Clin Psychopharm* 2016; 24: 226-34.
 16. Chisholm MA, Lance CE, Williamson GM, Mulloy LL. Development and validation of the immunosuppressant therapy adherence instrument (ITAS). *Patient Educ Couns* 2005; 59: 13-20.
 17. Madran BKÖ, Spivey CA, Chisholm-Burns MA. Immunosuppressant therapy adherence scale for transplant recipients: the study of validity and reliability. *Türkiye Klinikleri J Nurs Sci* 2016; 8: 325-34.
 18. Weng FL, Chandwani S, Kurtyka KM, Zacker C, Chisholm-Burns MA, Demissie K. Prevalence and correlates of medication non-adherence among kidney transplant recipients more than 6 months post-transplant: a cross-sectional study. *BMC Nephrol* 2013; 14: 261.
 19. Shemesh E, Shneider BL, Mazariegos GV. Weekend versus weekday adherence: do we, or do we not, thank God it's Friday? *Am J Transplant* 2020; 20: 7-9.
 20. Promraj R, Dumronggittigule W, Sirivatanauskorn Y, et al. Immunosuppressive medication adherence in liver transplant recipients. *Transplant Proc* 2016; 48: 1198-201.
 21. Regier DA, Kuhl EA, Kupfer DJ. The DSM-5: classification and criteria changes. *World Psychiatry* 2013; 12: 92-8.
 22. Yu S, Sussman S. Does Smartphone addiction fall on a continuum of addictive behaviors? *Int J Environ Res Public Health* 2020; 17: 422.
 23. Anderl C, Hofer MK, Chen FS. Directly-measured smartphone screen time predicts well-being and feelings of social connectedness. *J Soc Personal Relat* 2023; 41: 1073-90.
 24. Alageel AA, Alyahya RA, Y AB, et al. Smartphone addiction and associated factors among postgraduate students in an Arabic sample: a cross-sectional study. *BMC Psychiatry* 2021; 21: 302.
 25. Vlaminc H, Maes B, Evers G, et al. Prospective study on late consequences of subclinical non-compliance with immunosuppressive therapy in renal transplant patients. *Am J Transplant* 2004; 4: 1509-13.
 26. Killian MO, Little CW, Mayewski SE. Changes in medication adherence across the posttransplant period in pediatric organ transplant recipients. *Clin Transplant* 2024; 38: e15442.
 27. Tatoglu NKÖ, Ögce F. Factors affecting adherence of recipients to immunosuppressive therapy after liver and kidney transplantation. *J Educ Res Nurs* 2023; 20: 20-7.
 28. Jindal RM, Neff RT, Abbott KC, et al. Association between depression and nonadherence in recipients of kidney transplants: analysis of the United States renal data system. *Transplant Proc* 2009; 41: 3662-6.
 29. Tecen-Yucel K, Bayraktar-Ekincioglu A, Yıldırım T, Demirkan K, Erdem Y. Assessment of adherence to immunosuppressive treatment in kidney transplant patients: a descriptive study. *Türk J Nephrol* 2023; 32: 241-8.
 30. Sawicka O, Kocięba-Łaciak AH, Gałuszka D, Ślusarczyk K, Kasperowicz J. Parents' attitudes towards children's transplantology. *Arch Med Sci* 2024; 20: 326-31.
 31. Butler JA, Peveler RC, Roderick P, Smith PW, Horne R, Mason JC. Modifiable risk factors for non-adherence to immunosuppressants in renal transplant recipients: a cross-sectional study. *Nephrol Dial Transplant* 2004; 19: 3144-9.
 32. Griva K, Davenport A, Harrison M, Newman SP. Non-adherence to immunosuppressive medications in kidney transplantation: intent vs. forgetfulness and clinical markers of medication intake. *Ann Behav Med* 2012; 44: 85-93.
 33. Hu Y, Long X, Lyu H, Zhou Y, Chen J. Alterations in white matter integrity in young adults with smartphone dependence. *Front Hum Neurosci* 2017; 11: 532.
 34. Lee D, Namkoong K, Lee J, Lee BO, Jung YC. Lateral orbitofrontal gray matter abnormalities in subjects with problematic smartphone use. *J Behav Addict* 2019; 8: 404-11.
 35. Horvath J, Mundinger C, Schmitgen MM, et al. Structural and functional correlates of smartphone addiction. *Addict Behav* 2020; 105: 106334.
 36. Hartstein LE, Mathew GM, Reichenberger DA, et al. The impact of screen use on sleep health across the lifespan: a National Sleep Foundation consensus statement. *Sleep Health* 2024; 10: 373-84.
 37. Burkhalter H, Wirz-Justice A, Cajochen C, et al. Daytime sleepiness in renal transplant recipients is associated with immunosuppressive non-adherence: a cross-sectional, multi-center study. *Clin Transplant* 2014; 28: 58-66.
 38. Judice PB, Sousa-Sa E, Palmeira AL. Discrepancies between self-reported and objectively measured smartphone screen time: before and during lockdown. *J Prev* 2023; 44: 291-307.
 39. Sarris J, Thomson R, Hargraves F, et al. Multiple lifestyle factors and depressed mood: a cross-sectional and longitudinal analysis of the UK Biobank (N = 84,860). *BMC Med* 2020; 18: 354.
 40. Twenge JM, Blake AB, Haidt J, Campbell WK. Commentary: screens, teens, and psychological well-being: evidence from three time-use-diary studies. *Front Psychol* 2020; 11: 181.
 41. Burén J, Nutley SB, Thorell LB. Screen time and addictive use of gaming and social media in relation to health outcomes. *Front Psychol* 2023; 14: 1258784.
 42. Peng Y, Wang H, Fang Q, et al. Effectiveness of mobile applications on medication adherence in adults with chronic diseases: a systematic review and meta-analysis. *J Manag Care Spec Pharm* 2020; 26: 550-61.
 43. Ping Y, Visaria A, Suppiah SD, Tan YW, Malhotra R. Prevalence and correlates of medication reminder app 'use and use intention' among older adults. *Exp Res Clin Soc Pharm* 2022; 6: 100150.
 44. Robbins R, Krebs P, Jagannathan R, Jean-Louis G, Duncan DT. Health App use among US mobile phone users: analysis of trends by chronic disease status. *JMIR mHealth uHealth* 2017; 5: e197.
 45. Malinauskas R, Malinauskiene V. A meta-analysis of psychological interventions for Internet/smartphone addiction among adolescents. *J Behav Addict* 2019; 8: 613-24.
 46. Olson JA, Sandra DA, Chmoulevitch D, Raz A, Veissiere SPL. A nudge-based intervention to reduce problematic smartphone use: randomised controlled trial. *Int J Ment Health Addict* 2022; 1-23. 10.1007/s11469-022-00826-w.
 47. McGillicuddy J, Chandler J, Sox L, et al. "Smartphone Medication Adherence Saves Kidneys" for kidney transplantation recipients: protocol for a randomized controlled trial. *JMIR Res Protocols* 2019; 8: e13351.

48. Zhou L, Cheng K, Chen L, Hou X, Wan J. Effectiveness of eHealth for medication adherence in renal transplant recipients: systematic review and meta-analysis. *J Med Internet Res* 2025; 27: e73520.
49. Paneerselvam GS, Lua PL, Chooi WH, Rehman IU, Goh KW, Ming LC. Effectiveness of mobile apps in improving medication adherence among chronic kidney disease patients: systematic review. *J Med Internet Res* 2025; 27: e53144.